---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002074"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:26:08.244362+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rigel reports preliminary Q4 revenue ~$51.3M; launches REZLIDHIA for AML

## Summary
- Preliminary Q4 total revenue ~$51.3M including TAVALISSE $21.9M (+24% YoY) and REZLIDHIA $0.9M (launched Dec 22).
- Recognized $20M milestone from Kissei for Japan PMDA approval of TAVALISSE in chronic ITP; payment expected Q1 2023.
- Cash, equivalents and short-term investments ~$58.2M as of Dec 31, 2022 (vs $125.0M a year earlier).
- REZLIDHIA (olutasidenib) FDA approved for R/R AML with IDH1 mutation; commercial launch underway.
- First patients dosed in Phase 1b trial of R289 (IRAK1/4 inhibitor) for lower-risk MDS.

## SEC filing metadata
- accession: 0001104659-23-002074
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465923002074/0001104659-23-002074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465923002074/tm232596d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002074
- JSON: https://secwatch.observer/filing/0001104659-23-002074.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002074.txt

## Key facts
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported the fourth quarter ended December 31, 2022 results: revenue $51.3 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $51.3 million
  - Result: preliminary results
  source text: Preliminary fourth quarter 2022 Total Revenue of approximately $51.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465923002074/0001104659-23-002074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.